FIG 1A


2E+05
1.5E+05
1E+05
5E+04
0
Concentration (ng/mL)
0
90
180
270
360
450
540
Time (hr)
Concentration vs Time
3, IV
10, IV
30, IV
100, IV
300, IV
1000, IV
1000, SC
3000, IV
10000, IV

FIG 1B


1E+06
1E+05
1E+04
1000
100
10
1
0.1
Concentration (ng/mL)
0
90
180
270
360
450
540
Time (hr)
Concentration vs Time
3, IV
10, IV
30, IV
100, IV
300, IV
1000, IV
1000, SC
3000, IV
10000, IV

FIG 2A


8000
6000
4000
2000
0
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 2B


1E+04
1000
100
10
1
0.1
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 3A


2.5E+04
2E+04
1.5E+04
1E+04
5000
0
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 3B


1E+05
1E+04
1000
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 4A


3E+05
2E+05
1E+05
0
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 4B


1E+06
1E+05
1E+04
Concentration (ng/mL)
0
5
10
15
20
25
Time_after_Last_dose (hr)
Concentration vs Time
1, F
1, M
29, F
29, M

FIG 5A


500
450
400
350
300
250
200
150
100
50
0
IFNγ (pg/mL)
-1 1 2 4 5 8 9 15 16
Count 4 8 4 4 4 4 4 4 4
Median 11,465 8,57 6,665 7,245 40,8 7,07 109,7 50,65 211
Days
D1
D4
D8
D15

FIG 5B


IL6 (pg/mL)
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
-1 1 2 4 5 8 9 15 16
Count 4 8 4 4 4 4 4 4 4
Median 3,24 1,73 6,04 3,47 46,7 2,975 163,5 48,7 1650
Days
D1
D4
D8
D15

FIG 6A


IFNγ (pg/mL)
500
450
400
350
300
250
200
150
100
50
0
-1 1 2 4 5 8 9 15 16
Count 4 8 4 4 4 4 4 4 4
Median 12,55 10,385 6,4025 9,055 6,895 9,495 12,035 14,15 44,7
Days
D1
D4
D8
D15

FIG 6B


IL6 (pg/mL)
1200
1100
1000
900
800
700
600
500
400
300
200
100
0
-1 1 2 4 5 8 9 15 16
Count 4 8 4 4 4 4 4 4 4
Median 6,2 3,375 2,96 2,58 0,99 2,195 7,545 3,19 28,605
Days
D1
D4
D8
D15

Figure 7


Part 1A: A022600424 Monotherapy
Dose Escalation*
N=~48 (GPC3+ solid tumors)
DL1
DL2
DL3
DL4
DL5
DL6
DL7
After biological evidence of T cell activation is observed
Part 1B: Atezolizumab Combo
Dose Escalation
N=~18 (GPC3+ solid tumors)
DLX
DLX+1
DLX+2
Etc.
Part 2A: A022600424 Monotherapy
Expansion
N=40 (GPC3+ NSCLC)
Recommended dose(s)


1 mg N=4 (DL1A)
2.5 mg N=3 (DL2A)
3 mg N=2 (DL1)
4.5 mg N=4 (DL3A)
18 mg N=3 (DL4A)
36 mg N=4 (DL5A)
LLOQ 0.154
10000
1000
100
10
1
0.1
(log scale)
0
24
48
72
96
120
144
168
Time after 6th dosing (hour)
A022600424 mean plasma concentrations (ng/mL)

Figure 8

Figure 9


Treatment
Part 1A - DL1 A022600424 3 mg
Part 1A - DL1A A022600424 1 mg
Part 1A - DL2A A022600424 2.5 mg
Part 1A - DL3A A022600424 4.5 mg
Part 1A - DL4A A022600424 18 mg
Patient with CRS or not
N
Y
IFN gamma
IL-6
Result (pg/mL)
0
200
400
600
1000
2000
3000
Screening
Cycle 1 D1 SOI
Cycle 1 D2 24h post EOI
Cycle 1 D5 24h post EOI
Cycle 1 D9 24h post EOI
Cycle 1 D16 24h post EOI
Cycle 2 D2 24h post EOI
Visit

Figure 10


AFP Decrease ≥20%
From Baseline
Analysis Visit
Patient 1 (DL1)
Patient 2 (DL5A)
Patient 3
(DL1A)
Patient 4 (DL4A)
C2D1
C4D1
C2D1
C3D1
C2D1
C2D1
C3D1
C4D1
-59.59
-41.51
-30.63
-28.75
-56.51
-70.93
-38.28
-23.05